Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
Japan’s Ministry of Health, Labor and Welfare (MHLW) on September 29 ordered safety-related label revisions for nine immune checkpoint inhibitors to reflect the risks of severe gastritis and esophagitis, following a recent review by regulatory authorities. Seven of the checkpoint…
To read the full story
Related Article
REGULATORY
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…